Earlier Treatment of Prostate Cancer

Media Center
‌
‌
The treatment landscape in mHSPC has changed quite rapidly in the latest years. Listen to Dr Efstathiou’s thoughts on the past, present and future.

Categories / tags

Related media

Overlege Katarina Puco presenterer dataene på Erleada til behandling av mHSPC
Hør Overlege Katarina Puco ved Lovisenberg Sykehus presentere data på Erleada (apalutamid) til behandling av metastatisk hormonsensitiv prostatakreft som nå nylig ble godkjent i Beslutningsforum
An expanding Nordic platform advancing Multiple Myeloma studies and treatment​
There is growing optimism that multiple myeloma is on its way to become a chronic disease. The improving survival rate is partly attributed to the efforts of physicians like Dr. Fredrik Schjesvold from the Oslo Myeloma Center at Oslo University Hospital. Listen to our podcast as Dr. Schjesvold describes his efforts to build an infrastructure that will make Norway an attractive partner for early phase studies, and the progress that is being made to predict how well patients respond to treatment and the ability to identify the best, least toxic treatment option.
Treating myeloma patients: best treatment first, or save it for later?
With new innovative treatments becoming available, the way myeloma is perceived as a disease is changing. It has opened up the conversation on whether myeloma could become a chronic disease, or even curable in the future. However this paradigm shift also raise questions on whether to use new treatment early on, or keeping them to use in later lines. Listen to our third podcast in which Dr. Annette Vangsted talks about her perspective on how to treat multiple myeloma patients, and how to think about using new treatments and when.
An expanding Nordic platform advancing Multiple Myeloma studies and treatment​
There is growing optimism that multiple myeloma is on its way to become a chronic disease. The improving survival rate is partly attributed to the efforts of physicians like Dr. Fredrik Schjesvold from the Oslo Myeloma Center at Oslo University Hospital. Listen to our podcast as Dr. Schjesvold describes his efforts to build an infrastructure that will make Norway an attractive partner for early phase studies, and the progress that is being made to predict how well patients respond to treatment and the ability to identify the best, least toxic treatment option.
Advances, Possibilities and Challenges in MM Treatments
Sit back and listen to Ulf-Henrik Mellqvist talking about the significant developments in the field of multiple myeloma treatment. What do the new possibilities mean for patients and doctors? And why should young doctors looking to specialize go into hematology?
Treating myeloma patients: best treatment first, or save it for later?
With new innovative treatments becoming available, the way myeloma is perceived as a disease is changing. It has opened up the conversation on whether myeloma could become a chronic disease, or even curable in the future. However this paradigm shift also raise questions on whether to use new treatment early on, or keeping them to use in later lines. Listen to our third podcast in which Dr. Annette Vangsted talks about her perspective on how to treat multiple myeloma patients, and how to think about using new treatments and when.
© Janssen-Cilag AS 2023. Denne siden er utgitt av Janssen-Cilag AS Norge, som også er ansvarlig for innholdet Janssen-Cilag AS * Postboks 144 * NO-1325 Lysaker * Tel: +47 24 12 65 00 * Mail: [email protected] Siden er tiltenkt brukere fra Norge
Privacy PolicyTerms & conditionsCooky Policy
Cookie Settings
Logo